Departments of Radiology, Seoul National University Bundang Hospital, Gyeongi-Do, Korea.
AJNR Am J Neuroradiol. 2010 Nov;31(10):1817-23. doi: 10.3174/ajnr.A2180. Epub 2010 Jul 8.
An ESI for managing LBP is one of the most commonly performed interventions. The purpose of this observational study was to assess the effect of a therapeutic trial of a fluoroscopic interlaminar ESI for axial LBP and to analyze the outcome predictors.
All patients who received an interlaminar ESI for axial LBP at our facility in 2007 and 2008 were included. Initial short-term follow-up was done at <1 month after ESI. ESI was considered effective if patients had a reduction of >50% in their pain scores. In July 2009, telephone interviews were conducted by using formatted questions including the NASS patient-satisfaction index. The symptom-free interval was computed by the Kaplan-Meier method. Outcome predictors such as age, sex, duration of LBP, and MR imaging findings were statistically analyzed by the Mann-Whitney U and the Fisher exact tests.
Eighty-one patients (male/female = 16:65; mean age, 49.9 years; range, 17-77 years) were included in the study. The interlaminar ESI was effective in 63 of the 81 patients (77.8%) at initial short-term follow-up. For the 63 patients in whom ESI was effective, the median symptom-free interval was 154 days (95% CI, 96-212 days). Among 68 patients for whom telephone interviews were possible, 44 patients (64.7%) replied positively to the NASS patient satisfaction index (NASS patient-satisfaction index, 1 or 2). There were no significant outcome predictors.
The therapeutic trial of a fluoroscopic interlaminar ESI was effective for axial LBP without significant outcome predictors.
经皮内镜下腰椎间孔入路注射术(ESI)是治疗下腰痛(LBP)最常用的介入方法之一。本观察性研究旨在评估经皮内镜下腰椎间孔入路注射术治疗轴向 LBP 的疗效,并分析其预后预测因素。
纳入 2007 年至 2008 年期间在我院接受经皮内镜下腰椎间孔入路注射术治疗轴向 LBP 的所有患者。短期初始随访在 ESI 后<1 个月进行。如果患者的疼痛评分降低>50%,则认为 ESI 有效。2009 年 7 月,通过格式化问题进行电话访谈,包括 NASS 患者满意度指数。通过 Kaplan-Meier 方法计算无症状间隔。通过 Mann-Whitney U 和 Fisher 精确检验对年龄、性别、LBP 持续时间和 MRI 表现等预后预测因素进行统计学分析。
本研究共纳入 81 例患者(男/女=16/65;平均年龄 49.9 岁;范围 17-77 岁)。在短期初始随访中,81 例患者中有 63 例(77.8%)经皮内镜下腰椎间孔入路注射术有效。对于 63 例 ESI 有效的患者,无症状间隔的中位数为 154 天(95%CI,96-212 天)。在 68 例可进行电话访谈的患者中,44 例(64.7%)对 NASS 患者满意度指数(NASS 患者满意度指数,1 或 2)作出肯定回答。没有显著的预后预测因素。
经皮内镜下腰椎间孔入路注射术治疗轴向 LBP 有效,且无显著的预后预测因素。